US Generics — How the Economics Work
The largest export market and Rubicon's core engine. Understand ANDAs, Para IV, first-to-file, exclusivity, the Orange Book, price erosion and why FDA inspections are the single biggest revenue risk.
A primer on the United States generics market — the biggest export prize for Indian pharma and Rubicon's core arena. It explains the jargon, why prices collapse, and why a single factory inspection can sink revenue.
Read the '101' cards for the vocabulary (ANDA, Para IV, first-to-file…), then the chart for who has the most approvals, and the two panels for the two forces that drive the economics: price erosion and FDA compliance.
- ANDA
- — Abbreviated New Drug Application — proves a generic is equivalent to the brand, no new trials needed.
- First-to-file
- — The first filer to challenge a patent can win 180 days of exclusive generic sales — very lucrative.
- Price erosion
- — Generic prices fall 30–90% as more rivals launch the same molecule.
- Warning letter
- — A serious FDA compliance action that can halt approvals & shipments from a factory.
US Generics 101
The vocabulary every pharma operator and investor needs
Abbreviated New Drug Application — the FDA pathway to approve a generic by proving bioequivalence to a reference listed drug (RLD), without repeating clinical efficacy trials.
A patent certification in an ANDA asserting the RLD's patent is invalid or not infringed — triggering potential litigation and a path to early entry.
The first applicant(s) to file a substantially complete ANDA with a Para IV certification — eligible for 180 days of generic exclusivity.
A reward giving the FTF filer 180 days where FDA won't approve other generics — a high-value, limited window.
FDA's list of approved drugs with therapeutic-equivalence ratings and patent/exclusivity data — the map for generic strategy.
An 'AB' rating means a generic is pharmaceutically equivalent and bioequivalent — substitutable at the pharmacy.
The brand sold as a generic (often via a partner) — used defensively to capture generic share, intensifying erosion.
Generic prices fall as competitors enter — often 30-90% in the first 1-2 years; the core economic risk of US generics.
Three buying consortia control ~90%+ of US generic purchasing — squeezing supplier pricing power.
A warning letter or import alert at a key facility can halt approvals & shipments — the single largest revenue risk for exporters.
ANDA Approvals by Company
Cumulative approved ANDAs · top US-exposed Indian players (illustrative)
Why price erosion happens
- • Each new generic entrant takes share and cuts price — by competitor #4-5 the price can be 70-90% below brand.
- • Three buying consortia (McKesson/Cencora/Cardinal-linked) control ~90% of purchasing, squeezing supplier margins.
- • Authorized generics (the brand-as-generic) accelerate erosion further.
- • The defence is complexity: fewer competitors on hard-to-make forms means durable price & margin — Rubicon's strategy.
Why FDA inspections dominate the risk
- • A warning letter or import alert at a key site can halt new approvals and block shipments — instantly impairing revenue.
- • Outcomes: NAI (no action) → VAI (voluntary action) → OAI (official action / warning letter).
- • Facility concentration multiplies the risk — single-site dependence is a red flag.
- • AI leverage: data-integrity monitoring, inspection war-room, deviation/CAPA copilots (see the AI Map).